non-small cell lung cancer
4 stories in The Vital Record · Condition
-
· Biotech Business
GSK to buy Nuvalent for $10.6 billion, betting on two investigational lung-cancer drugs awaiting FDA decisions -
· Clinical Trials
Neoadjuvant Osimertinib Meets Pathology Endpoint (~25% vs 2%) in a Phase III Resectable EGFR-Mutant Lung Cancer Trial — Survival Signal Not Yet Significant -
· Opinion
When the challenger loses to the standard of care, listen -
· Research
Adjuvant nivolumab does not extend disease-free survival after lung cancer surgery in NCI trial